You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

https://doi.org/10.1136/jitc-2023-006833corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lo Russo G, Prelaj A, Dolezal J, et al.PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J ImmunoTher Cancer 2023;11:e006833. doi: 10.1136/jitc-2023-006833

    In this article, affiliation 12 has been updated to: Oncology Department, Mario Negri Institute for Pharmacological Research (IRCCS), Milano, Lombardia, Italy.